EDUCATION AND POSITIONS HELD:
- Ph.D., Graduate Institute of Epidemiology, School of Public Health, National Taiwan University, Taipei, Taiwan (2006)
- Postdoctoral Fellow, Genomics Research Center, Academia Sinica, Taipei, Taiwan (2006- 2011)
- Associate Professor, Graduate Institute of Clinical Medicine, China Medical University, Taichung, Taiwan (2011 - 2013)
- Associate Research Fellow, Molecular and Genomic Epidemiology Center (MaGEC), China Medical University Hospital, Taichung, Taiwan (2011 - 2013)
- Associate Professor, Genomics Research Center, Academia Sinica, Taipei, Taiwan (2012 - present)
- Adjunct Associate Professor, Graduate Institute of Clinical Medicine, National Yang-Ming University (2014 – present)
- Deputy Director, Genomics Research Center, Academia Sinica (2019-present)
- Prof. K-P Chen Award for the Best Public Health Paper, Taiwan Public Health Association (2004)
- Honorary Member, Phi Tau Phi Scholastic Honor Society (2006)
- Distinguished Postdoctoral Scholar of Academia Sinica (2007-2008)
- The 20th Wang Ming-Ning Award (2010; as a member of the REVEAL-HBV study group led by Prof. Chien-Jen Chen)
- Ta-You Wu Memorial Award, National Science Council, Taiwan (2013)
- The 2013 Award for Outstanding Contributions in Science and Technology, Executive Yuan (2013; co-awardee: Prof. Chien-Jen Chen and Dr. Mei-Hsuan Lee)
- Epidemiology of viral hepatitis: Delineating incidence and determinants (including viral, host, and environmental factors) of milestone transitions and disease progression in the natural history of chronic hepatitis B and C using longitudinal follow-up study.
- Development of risk prediction scores: Derivation and validation of risk prediction instruments which integrated multiple clinical parameters for the prediction of progression and adverse sequelae of chronic hepatitis B and C.
- Delineating etiology and Identifying high risk group of liver diseases among populations without chronic viral Hepatitis.
- Biomarkers for early detection of cancers: Exploring useful multi-omics pre-diagnostic biosignatures for predicting major cancers in order to develop novel tactics in early diagnosis and preventive measures.